Investors like biotechnology stocks for their explosive growth potential. Smaller biotechs usually don’t have approved products on the market yet, and this keeps investors on their toes. Because candidate drugs that become approved translate into significant share price gains. With that in mind, EDIT stock is on the radar today.
Will shares of Editas Medicine (NASDAQ:EDIT) break out?
EDIT StockWith a market cap of $1.10 billion, Editas Medicine is a valuable company for one that has yet to get a product to market. Shares are currently priced at $22.31 USD on the NASDAQ ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.